Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
The first presentation by Dr. Cox is entitled "Sutureless Surgical AorticValve Replacement: The Enable Valve." The ATS Enable(R) Aortic Bioprosthesisis the same valve as the traditionally sutured ATS 3f(R) Aortic Bioprosthesis,but mounted on a Nitinol self-expanding frame. The ATS 3f Enable eliminatesthe need for traditional suturing of aortic replacement valves, savingvaluable cardiopulmonary bypass and aortic cross clamp time providing surgeonsand patients with a minimally invasive alternative to traditional open chestprocedures.
Advertisement
Dr. Cox, the original founder of the Maze procedure, will also present"Surgical Options and Results for Atrial Fibrillation: Historical Overview andCurrent Approaches." As the Medical Director for ATS, Dr. Cox wasinstrumental in the development of the ATS CryoMaze(R) Clamp which wasrecently launched in the US. He has hosted several ATS educational symposia,bringing together the thought leaders in the surgical treatment of AF and heis the architect of the Company's world class AF advisory board.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused oncardiac surgery. The Company, global in scope, is headquartered inMinneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves,which utilize a unique pivot design resulting in exceptional performance andlow risk profile, have been implanted in patients worldwide. The ATS 3f(R)brand encompasses multiple tissue heart valve product offerings at varyingsteps from market introductions to clinical trials to development projectsthat incorporate less invasive valve replacement technology. ATS Medical'sfocus on serving the cardiac surgery community is further strengthened byofferings that include ATS Simulus(R) annuloplasty products for heart valverepair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical website is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may includestatements regarding intent, belief or current expectations of the Company andits management. Actual results could differ materially from those projected inthe forward-looking statements as a result of a number of important factors,including the results of clinical trials, the timing of regulatory approvals,the integration of 3f Therapeutics and the surgical cryoablation business ofCryoCath Technologies, Inc., regulatory actions, competition, pricingpressures, supplier actions and management of growth. For a discussion ofthese and other risks and uncertainties that could affect the Company'sactivities and results, please refer to the Company's filings with theSecurities and Exchange Commission, including its Form 10-K for the year endedDecember 31, 2007 and its most recent quarterly report on Form 10-Q.
SOURCE ATS Medical, Inc.
